Resistance to commonly used Helicobacter pylori eradication regimens in some cases leads to unsatisfactory results in eradicating Helicobacter in patients infected with H. pylori.

An open-label, prospective study in the United States evaluated the efficacy of a new 4-component regimen comprising 3 antibiotics (levofloxacin, nitazoxadine and doxycycline) and an omeprazole proton pump inhibitor in eradicating H. pylori in patients who have not previously received anti-Helicobacter pylori treatment.

This study involved patients with H. diagnosed gastritis or peptic ulcer associated with pylori, confirmed by PGF and determination of H. pylori antigens in the feces. All patients were included in the 6 week “wash period” following the use of antibiotics or proton pump inhibitors, after which they were randomized to receive either 4 component regimens (LOAD), including levofloxacin (250 mg morning before breakfast), nitazoxadine (500 mg 2 times morning and evening), doxycycline (100 mg evening) and omeprazole (40 mg morning before breakfast) for 7 or 10 days or a 3-component regimen (LAC), including lansoprazole (30 mg in the morning), amoxicillin (1 g 2 times morning and evening) and clarithromycin (500 mg 2 times daily rum and evening).

Eradication of H. pylori was confirmed by the determination of H. pylori antigens in the faeces at least 4 weeks after the end of treatment.

According to the analysis, a statistically significant difference (p less than 0.05) in the frequency of eradication H was found in the population of patients to be treated (ITT population). pylori when using 4-component regimens for 7 or 10 days (CHARGE 10 - 88.9%, CHARGE 7 - 90%) compared to 3-component mode (LAC - 73.3%).

There were no statistically significant differences in the frequency of occurrence and the structure of adverse events between the groups compared.

Thus, in this open and prospective study, it has been demonstrated that the use of the Helicobacter pylori 4-component eradication scheme is very effective in eradicating H. pylori in patients who have not yet received eradication treatment.